Glenmark announced the deal in a Bombay Stock Exchange (BSE) filing. It said that under the agreement, ‘these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorisations and commercialise the products in North America’.

The agreement for the ophthalmic products is ‘aligned with the company's strategy to strengthen its focus on complex generic formulations’, said Robert Matsuk, President, North America & Global API at Glenmark. He added that ‘our strategic partnership with SCD supports our objective to expand the product offerings of our complex generic portfolio’.

The company expects to file six abbreviated new drug applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS, Glenmark says that US brand-name sales for the six products was approximately US$1.7 billion for 2017.

Related article
Glenmark gains approval for anti-epileptic generic

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.